YOUNES, A. Et Al. 2017. Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. ASH 2017 .

YOUNES, A., BRODY, J., CECİLİA, C., LOPEZ, A., YEHUDA, D. B., FERHANOĞLU, A. B., ... NAGLER, A.(2017). Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia . ASH 2017

YOUNES, ANAS Et Al. "Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia," ASH 2017, 2017

YOUNES, ANAS Et Al. "Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia." ASH 2017 , 2017

YOUNES, A. Et Al. (2017) . "Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia." ASH 2017 .

@conferencepaper{conferencepaper, author={ANAS YOUNES Et Al. }, title={Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia}, congress name={ASH 2017}, city={}, country={}, year={2017}}